News for Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals, Inc.'s FDA-granted exclusivity for Voquezna positions it as a GI market leader. Click here to find out why PHAT stock is a Buy.

Phathom Pharmaceuticals (PHAT) has received a positive update from the analyst Chase Knickerbocker at Craig-Hallum. The latest data indicates that Craig-Hallum

Craig-Hallum has increased its price target for Phathom Pharmaceuticals (PHAT) from $12 to $17, while maintaining a Buy rating on the stock. This adjustment com

On June 9, 2025, Phathom Pharmaceuticals (PHAT) received a reiteration of its rating from the financial services firm HC Wainwright & Co. Analyst Matthew Caufie

On May 29, 2025, Carlyle Group Inc. (Trades, Portfolio) executed a significant transaction involving StandardAero Inc. The firm reduced its holdings in Standard

Phathom Pharmaceuticals (PHAT) continues to maintain its strong market position, as Needham analyst Joseph Stringer reaffirms a "Buy" rating for the company. Th

Phathom Pharmaceuticals (PHAT) saw its stock surge by over 95% after announcing a favorable decision from the Food and Drug Administration (FDA). The FDA has ap

U.S. stocks rallied sharply on Friday, June 6, 2025, as markets closed the week on a positive note following a stronger-than-expected jobs report and easing

Phathom Pharmaceuticals Inc. (PHAT) stock soared 95% to $9.17, with an intraday high of $12.32, after the FDA approved its Citizen Petition, granting 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets until May 3, 2032. VOQUEZNA, a first-in-class potassium-competitive acid blocker, is marketed for heartburn relief in…

Cantor Fitzgerald has increased its price target for Phathom Pharmaceuticals (PHAT) from $23 to $29, while maintaining an Overweight rating on the shares. The i

U.S. stock futures were lower this morning, with the Dow futures falling around 400 points on Wednesday. Shares of Palo Alto Networks, Inc. PANW fell in pre-ma...

FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. ( PHAT), a biopharmaceutical company focused on developing and commercializ

**media[625360]**

Key Highlights: Phathom Pharmaceuticals sees a 50% surge in stock price driven by insider buying. Analysts project significant potential upside, despite

On May 7, 2025, Asit Parikh, a Director at Phathom Pharmaceuticals Inc (PHAT), purchased 10,000 shares of the company. Following this transaction, the insider n

FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. ( PHAT), a biopharmaceutical company focused on developing and commercializ

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call May 1, 2025 8:00 AM ETCompany ParticipantsEric Sciorilli - Head, Investor RelationsSteve...

VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million

Phathom Pharmaceuticals (PHAT) reported first-quarter revenue of $28.519 million, slightly below the market expectation of $29.02 million. The company is steeri